Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 5

Augmentation treatment in major depressive disorder: focus on aripiprazole

Authors J Craig Nelson, Andrei Pikalov, Robert M Berman

Published 10 October 2008 Volume 2008:4(5) Pages 937—948

DOI http://dx.doi.org/10.2147/NDT.S3369

Review by Single-blind

Peer reviewer comments 3

J Craig Nelson1, Andrei Pikalov2, Robert M Berman3

1University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USA

Abstract: Major depressive disorder (MDD) is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these efficacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.

Keywords: major depression, antipsychotic, mood disorder, aripiprazole

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Berman R, Thase M, Trivedi M, Hazel JA, Marler S, McQuade R, Carson W, Baker R, Marcus R

Neuropsychiatric Disease and Treatment 2011, 7:303-312

Published Date: 24 May 2011

Readers of this article also read:

Factors associated with group bullying and psychopathology in elementary school students using child-welfare facilities

Kim JW, Lee K, Lee YS, Han DH, Min KJ, Song SH, Park GN, Lee JY, Kim JO

Neuropsychiatric Disease and Treatment 2015, 11:991-998

Published Date: 7 April 2015

Surgery in asymptomatic patients with colorectal cancer and unresectable liver metastases: the authors' experience

Boselli C, Renzi C, Gemini A, Castellani E, Trastulli S, Desiderio J, Corsi A, Barberini F, Cirocchi R, Santoro A, Parisi A, Redler A, Noya G

OncoTargets and Therapy 2013, 6:267-272

Published Date: 27 March 2013

Preparation and in vitro studies of MRI-specific superparamagnetic iron oxide antiGPC3 probe for hepatocellular carcinoma

Li Y, Chen Z, Li F, Wang J, Zhang Z

International Journal of Nanomedicine 2012, 7:4593-4611

Published Date: 22 August 2012

Further data on the association between Helicobacter pylori infection and primary open-angle glaucoma

Zavos C, Kountouras J

Clinical Ophthalmology 2012, 6:243-245

Published Date: 10 February 2012

Prevention of acute graft-versus-host disease by magnetic nanoparticles of Fe3O4 combined with cyclosporin A in murine models

Cheng J, Zhou Y, Chen B, Wang J, Xia G, Jin N, Ding J, Gao C, Chen G, Miao Y, Li W, Liu Z, Wang X

International Journal of Nanomedicine 2011, 6:2183-2189

Published Date: 3 October 2011

Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy

Aarat M Patel, Larry W Moreland

Drug Design, Development and Therapy 2010, 4:263-278

Published Date: 1 October 2010

Recurrent optic neuritis: clues from a long-term follow up study of recurrent and bilateral optic neuritis patients

Asli Kurne, Rana Karabudak, Gul Yalcin-Cakmakli, et al

Eye and Brain 2010, 2:15-20

Published Date: 9 March 2010

Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index

Kefei Hu, Saideh Berenjian, Rolf Larsson, et al

International Journal of Nanomedicine 2010, 5:51-62

Published Date: 6 January 2010

Comparison of skin microvascular reactivity with hemostatic markers of endothelial dysfunction and damage in type 2 diabetes

Sandra Beer, François Feihl, Juan Ruiz, Irène Juhan-Vague, Marie-Françoise Aillaud, et al

Vascular Health and Risk Management 2008, 4:1449-1458

Published Date: 5 December 2008

Preparation and biomedical application of a nonpolymer coated superparamagnetic nanoparticle

Lin Du, Jianzhao Chen, Yanting Qi, Dan Li, Chonggang Yuan

International Journal of Nanomedicine 2007, 2:805-812

Published Date: 15 January 2008